focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,785.00
Bid: 1,784.50
Ask: 1,785.00
Change: -27.50 (-1.52%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,782.00
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

8 Jul 2022 15:10

RNS Number : 8965R
GSK PLC
08 July 2022
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

462

£17.8560

384

 

£17.8560

575

d)

Aggregated information

 

 

Aggregated volume Price

 

1,421

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I Mackay

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

311

£17.8560

266

£17.8560

397

d)

Aggregated information

 

 

Aggregated volume Price

 

974

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 1 July 2022 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.7500

262

$43.7500

198

$43.7500

314

d)

Aggregated information

 

 

Aggregated volume Price

 

774

$43.7500

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

 

b)

Position/status

President, Vaccines and Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

145

£17.8560

84

£17.8560

97

d)

Aggregated information

 

 

Aggregated volume Price

 

326

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

60

£17.8560

55

£17.8560

90

d)

Aggregated information

 

 

Aggregated volume Price

 

205

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

85

£17.8560

67

£17.8560

111

d)

Aggregated information

 

 

Aggregated volume Price

 

263

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

36

£17.8560

33

£17.8560

51

d)

Aggregated information

 

 

Aggregated volume Price

 

120

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 1 July 2022 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.7500

48

$43.7500

60

$43.7500

33

d)

Aggregated information

 

 

Aggregated volume Price

 

141

$43.7500

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

139

£17.8560

104

£17.8560

189

d)

Aggregated information

 

 

Aggregated volume Price

 

432

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 1 July 2022 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.7500

19

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

 

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

102

£17.8560

81

£17.8560

125

d)

Aggregated information

 

 

Aggregated volume Price

 

308

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

72

£17.8560

61

£17.8560

113

d)

Aggregated information

 

 

Aggregated volume Price

 

246

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

59

£17.8560

47

£17.8560

79

d)

Aggregated information

 

 

Aggregated volume Price

185

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO, ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.8560

98

£17.8560

83

d)

Aggregated information

 

 

Aggregated volume Price

 

181

£17.8560

e)

Date of the transaction

2022-07-05

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSSUFLAEESESW
Date   Source Headline
15th Dec 20217:00 amRNSGSK/Sanofi COVID-19 vaccine booster & Ph3 update
13th Dec 202111:25 amRNSDirector/PDMR Shareholding
9th Dec 20214:35 pmRNSDirector/PDMR Shareholding
7th Dec 202112:00 pmRNSMedicago/GSK COVID-19 vaccine positive Ph3 data
7th Dec 20217:07 amRNSSotrovimab retains its activity vs Omicron variant
2nd Dec 20217:02 amRNSSotrovimab retains its activity vs Omicron variant
1st Dec 202111:05 amPRNTotal Voting Rights
24th Nov 20214:17 pmRNSDirector/PDMR Shareholding
24th Nov 20214:00 pmRNSGSK publishes provisional 2022 dividend dates
23rd Nov 20213:06 pmRNSDirector/PDMR Shareholding
17th Nov 20217:00 amRNSNucala approved in Europe for more indications
15th Nov 20214:37 pmRNSBlock listing Interim Review
12th Nov 202112:00 pmRNSPhase III IM administration data for sotrovimab
12th Nov 20219:23 amRNSDirector/PDMR Shareholding
10th Nov 202111:28 amRNSDirector/PDMR Shareholding
5th Nov 20215:33 pmRNSGSK shares positive Phase III data for daprodustat
1st Nov 20215:11 pmRNSTotal Voting Rights
27th Oct 20212:23 pmRNSDirector/PDMR Shareholding
27th Oct 202112:00 pmRNS3rd Quarter Results
27th Oct 20219:00 amRNSDirectorate Change
15th Oct 20212:41 pmRNSDirector/PDMR Shareholding
14th Oct 20214:31 pmRNSDirector/PDMR Shareholding
14th Oct 20214:28 pmRNSDirector/PDMR Shareholding
13th Oct 20211:55 pmRNSDirector/PDMR Shareholding
12th Oct 20213:17 pmRNSDirector/PDMR Shareholding
12th Oct 20211:36 pmRNSDirector/PDMR Shareholding
12th Oct 20211:33 pmRNSDirector/PDMR Shareholding
12th Oct 20211:30 pmRNSDirector/PDMR Shareholding
12th Oct 20211:28 pmRNSDirector/PDMR Shareholding
1st Oct 202111:54 amRNSTotal Voting Rights
24th Sep 20215:28 pmRNSDirector/PDMR Shareholding
22nd Sep 20213:58 pmRNSDirector/PDMR Shareholding
20th Sep 20212:42 pmRNSDirector Declaration
13th Sep 20215:26 pmRNSDirector/PDMR Shareholding
9th Sep 20214:42 pmRNSDirector/PDMR Shareholding
7th Sep 20214:54 pmRNSDirector/PDMR Shareholding
3rd Sep 20219:32 amRNSDirector/PDMR Shareholding
1st Sep 202111:44 amRNSTotal Voting Rights
31st Aug 20217:00 amRNSSK bio & GSK start Ph3 Covid-19 vaccine trial
25th Aug 20212:01 pmRNSDirector/PDMR Shareholding
23rd Aug 20214:39 pmRNSDirector/PDMR Shareholding
13th Aug 20219:38 amRNSDirector/PDMR Shareholding - amendment
11th Aug 20212:18 pmRNSDirector/PDMR Shareholding
11th Aug 202112:34 pmRNSDirector/PDMR Shareholding
5th Aug 20219:00 amRNSBlock Listing Application
2nd Aug 20212:23 pmRNSTotal Voting Rights
28th Jul 20215:32 pmRNSDirector/PDMR Shareholding
28th Jul 202112:00 pmRNS2nd Quarter Results
26th Jul 20214:59 pmRNSDirector/PDMR Shareholding
23rd Jul 20212:32 pmRNSBoard Committee Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.